InsiderClue
← All stocks

Fulcrum Therapeutics, Inc.

FULC Net selling
CIK 0001680581 #3613 in the set updated 17 Sep 2026
Bought (12 mo)
$1.49M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$58.99M
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$58.99M
8 of 8 sales
Net
−$57.51M
−$57.51M against sales at will

By person

6 insiders · 14 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
RA CAPITAL MANAGEMENT, L.P. entity
10% owner
—
$58.38M (3)
−$58.38M
6,053,960
7.93%
$21.31M
−40.8%
TANG KEVIN
10% owner
$1.49M (6)
—
+$1.49M
7,080,945
9.28%
$24.92M
+6.3%
Gould Robert J
Director
—
$504.44K (3)
−$504.44K
454,864
0.5962%
$1.60M
−9.0%
Ezekowitz Alan
Director
—
$65.61K (1)
−$65.61K
10,927
0.0143%
$38.46K
−62.2%
Oltmans Curtis Gale
Chief Legal Officer
—
$44.60K (1)
−$44.60K
10,252
0.0134%
$36.09K
−25.2%
Tourangeau Greg
Principal Accounting Officer
—
—
—
14,062
0.0184%
$49.50K
−3.4%

Individual transactions

14
Insider
Date
Role
Action
Shares
Price
Amount
TANG KEVIN
17 Jul 2026
10% owner
Buy indirect
50,945
$3.52
$179.33K
TANG KEVIN
16 Jul 2026
10% owner
Buy indirect
116,671
$3.56
$415.35K
TANG KEVIN
15 Jul 2026
10% owner
Buy indirect
107,377
$3.56
$382.26K
TANG KEVIN
14 Jul 2026
10% owner
Buy indirect
75,952
$3.58
$271.91K
TANG KEVIN
14 Jul 2026
10% owner
Buy indirect
53,651
$3.56
$191.00K
TANG KEVIN
13 Jul 2026
10% owner
Buy indirect
12,966
$3.54
$45.90K
Ezekowitz Alan
26 Jun 2026
Director
Sell
18,000
$3.65
$65.61K
Gould Robert J
2 Feb 2026
Director
Sell
15,000
$10.72
$160.86K
Gould Robert J
2 Jan 2026
Director
Sell
15,000
$11.87
$178.09K
Oltmans Curtis Gale
15 Dec 2025
Chief Legal Officer
Sell
3,452
$12.92
$44.60K
RA CAPITAL MANAGEMENT, L.P.
8 Dec 2025
10% owner
Sell indirect
91,722
$14.98
$1.37M
RA CAPITAL MANAGEMENT, L.P.
8 Dec 2025
10% owner
Sell indirect
2,706,397
$14.28
$38.65M
RA CAPITAL MANAGEMENT, L.P.
8 Dec 2025
10% owner
Sell indirect
1,377,020
$13.33
$18.36M
Gould Robert J
19 Nov 2025
Director
Sell
15,000
$11.03
$165.50K

What was left out

Form 4 filings counted 21
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 8
Transactions with no price 0
Shares from compensation/vesting 0
History held since 18 Jul 2019